Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Mundipharma, Helsinn Expand Cancer Collaboration | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Mundipharma, Helsinn Expand Cancer Collaboration

Licensing and distribution deal for the anti-emetic agent Aloxi now covers Vietnam

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Mundipharma and Helsinn Group signed a licensing and distribution agreement for the anti-emetic agent Aloxi in Vietnam, extending an international collaboration. Aloxi (palonosetron hydrochloride), a 5-HT3 receptor antagonist, has been approved in Vietnam for the treatment of Chemotherapy-Induced Nausea and Vomiting (CINV), one of the most common side effects of cancer chemotherapy.

“This important extension of our portfolio in Vietnam offers relief to patients suffering from the side effects of chemotherapy and enables patients and healthcare providers to benefit from our expertise in this area,” said Raman Singh, chief executive officer, Mundipharma.

Riccardo Braglia, vice chairman and chief executive officer, Helsinn Group, said, “Helsinn and Mundipharma have an effective, longstanding partnership and Mundipharma successfully markets, promotes and distributes a number of our products across a range of territories. We’re delighted to be able to extend this relationship through this agreement.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters